Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS212 combined with JS111 in EGFR-mutant advanced non-small cell lung cancer
CTR20261258Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JS212, js111 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2026; status: active.
02
Drugs
JS212js111
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261258.